Neurovascular mechanisms of Alzheimer's neurodegeneration

In contrast to traditional neuroncentric views of Alzheimer's disease (AD), recent findings indicate that neurovascular dysfunction contributes to cognitive decline and neurodegeneration in AD. Here, I propose the neurovascular hypothesis of AD, suggesting that faulty clearance of amyloid beta peptide (A beta) across the blood-brain barrier (BBB), aberrant angiogenesis and senescence of the cerebrovascular system could initiate neurovascular uncoupling, vessel regression, brain hypoperfusion and neurovascular inflammation. Ultimately, this would lead to BBB compromise, to chemical imbalance in the neuronal environment and to synaptic and neuronal dysfunction, injury and loss. Based on the neurovascular hypothesis, I suggest an array of new potential therapeutic approaches that could be developed for AD, to enhance A beta clearance and neurovascular repair, and to protect the neurovascular unit from divergent inducers of injury and apoptosis.

[1]  M. Mullan,et al.  β-Amyloid-mediated vasoactivity and vascular endothelial damage , 1996, Nature.

[2]  J. Morrison,et al.  The aging brain: morphomolecular senescence of cortical circuits , 2004, Trends in Neurosciences.

[3]  B. Zlokovic.  Clearing amyloid through the blood–brain barrier , 2004, Journal of neurochemistry.

[4]  A. Hofman,et al.  Silent brain infarcts and the risk of dementia and cognitive decline. , 2003, The New England journal of medicine.

[5]  D. Holtzman,et al.  Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  José A Fernández,et al.  Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective , 2003, Nature Medicine.

[7]  M. Roth.  The natural history of mental disorder in old age. , 1955, The Journal of mental science.

[8]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[9]  Peter J. Lenting,et al.  LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms , 2004, Neuron.

[10]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[11]  S. Paul,et al.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.

[12]  A. Hofman,et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.

[13]  B. Hyman,et al.  Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy , 2002, The Journal of Neuroscience.

[14]  José A Fernández,et al.  Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C , 2004, Nature Medicine.

[15]  Thomas G. Beach,et al.  Atherosclerosis of Cerebral Arteries in Alzheimer Disease , 2004, Stroke.

[16]  H. Vinters,et al.  Smooth muscle cells and the pathogenesis of cerebral microvascular disease ("angiomyopathies"). , 2003, Experimental and molecular pathology.

[17]  P. Scheltens,et al.  Advances in the early detection of Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[18]  R. Tanzi,et al.  Clearance of Alzheimer's Aβ Peptide The Many Roads to Perdition , 2004, Neuron.

[19]  A. Fagan,et al.  Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease , 2002, Neurobiology of Disease.

[20]  M. Emmerling,et al.  High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. , 1999, Biochemical and biophysical research communications.

[21]  L. Hayflick,et al.  The illusion of cell immortality , 2000, British Journal of Cancer.

[22]  T. Wyss-Coray,et al.  Adult mouse astrocytes degrade amyloid-β in vitro and in situ , 2003, Nature Network Boston.

[23]  Eric J Topol,et al.  Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins , 2004, The Lancet.

[24]  I. Komuro,et al.  Vascular cell senescence and vascular aging. , 2004, Journal of molecular and cellular cardiology.

[25]  Hyun Seok Song,et al.  SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier , 2003, Nature Medicine.

[26]  J. C. Torre.  Alzheimer's disease is a vasocognopathy: a new term to describe its nature. , 2004 .

[27]  R. Tanzi,et al.  Clearance of Alzheimer's Aβ PeptideThe Many Roads to Perdition , 2004 .

[28]  P. Gorelick,et al.  Risk Factors for Vascular Dementia and Alzheimer Disease , 2004, Stroke.

[29]  Maiken Nedergaard,et al.  Astrocyte-mediated control of cerebral microcirculation , 2003, Trends in Neurosciences.

[30]  D. Begley,et al.  Structural and functional aspects of the blood-brain barrier. , 2003, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[31]  Peter B. Reiner,et al.  β‐Amyloid efflux mediated by p‐glycoprotein , 2001 .

[32]  T. Beach,et al.  Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease , 2004, Neurological research.

[33]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[34]  D. Holtzman,et al.  Plaque‐associated disruption of CSF and plasma amyloid‐β (Aβ) equilibrium in a mouse model of Alzheimer's disease , 2002, Journal of neurochemistry.

[35]  D. Holtzman,et al.  Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease , 2002, Science.

[36]  O. Lindvall,et al.  Neurogenesis after ischaemic brain insults , 2003, Current Opinion in Neurobiology.

[37]  David A. Snowdon,et al.  Healthy Aging and Dementia: Findings from the Nun Study , 2003, Annals of Internal Medicine.

[38]  D. Coppola,et al.  Inhibition of Angiogenesis by Aβ Peptides , 2004, Angiogenesis.

[39]  S. Goldman,et al.  New roles for astrocytes: Redefining the functional architecture of the brain , 2003, Trends in Neurosciences.

[40]  P. Hof,et al.  The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease , 2004, Neurological research.

[41]  Bruce J Aronow,et al.  ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition Evidence that ApoE Regulates Extracellular Aβ Metabolism In Vivo , 2004, Neuron.

[42]  M. C. Angulo,et al.  Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation , 2003, Nature Neuroscience.

[43]  G. Silverberg,et al.  Alzheimer's disease, normal‐pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis , 2003, The Lancet Neurology.

[44]  Frank R. Ervin,et al.  Alzheimer's Disease Aβ Vaccine Reduces Central Nervous System Aβ Levels in a Non-Human Primate, the Caribbean Vervet , 2004 .

[45]  P. Dore‐Duffy,et al.  Role of the CNS microvascular pericyte in the blood‐brain barrier , 1998, Journal of neuroscience research.

[46]  N. Patel,et al.  Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis , 2004, Neuroscience Letters.

[47]  D. Borchelt,et al.  SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein , 1999, Nature Neuroscience.

[48]  C. Iadecola,et al.  Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[49]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[50]  José A Fernández,et al.  Activated Protein C Prevents Neuronal Apoptosis via Protease Activated Receptors 1 and 3 , 2004, Neuron.

[51]  C. Iadecola.  Neurovascular regulation in the normal brain and in Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[52]  D. Holtzman,et al.  In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.

[53]  P. Luiten,et al.  Cerebral microvascular pathology in aging and Alzheimer's disease , 2001, Progress in Neurobiology.

[54]  R. Deane,et al.  Early-onset and Robust Cerebral Microvascular Accumulation of Amyloid β-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid β-Protein Precursor* , 2004, Journal of Biological Chemistry.

[55]  E. Newman.  New roles for astrocytes: Regulation of synaptic transmission , 2003, Trends in Neurosciences.

[56]  S. Greenberg,et al.  Pathogenic Effects of D23N Iowa Mutant Amyloid β-Protein* , 2001, The Journal of Biological Chemistry.

[57]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[58]  D. Selkoe.  Clearing the Brain's Amyloid Cobwebs , 2001, Neuron.

[59]  Eric E. Smith,et al.  Amyloid Angiopathy–Related Vascular Cognitive Impairment , 2004, Stroke.

[60]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[61]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[62]  T. Saido,et al.  Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.

[63]  C. Lemere,et al.  Novel Therapeutic Approach for the Treatment of Alzheimer's Disease by Peripheral Administration of Agents with an Affinity to β-Amyloid , 2003, The Journal of Neuroscience.

[64]  H. Vinters,et al.  Amyloidosis of cerebral arteries. , 2003, Advances in neurology.

[65]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[66]  M. Mattson,et al.  Aging in the mind , 2004, Trends in Neurosciences.

[67]  E. Matsubara,et al.  Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Mark S. Cohen,et al.  Patterns of brain activation in people at risk for Alzheimer's disease. , 2000, The New England journal of medicine.